Immunotoxicity of monoclonal antibodies

References

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 497
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548 - 558
   PubMed Web of Science ®Google Scholar
• Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Exp Opin Drug Metab Toxicol 2008; 4:1537 - 1549
   PubMed Web of Science ®Google Scholar
• Descotes J. Descotes J. Health consequences of immunotoxic effects. Immunotoxicology of Drugs and Chemicals. An Experimental and Clinical Approach. Vol. 1 Principles and Methods of Immunotoxicology 2004; Amsterdam Elsevier Science 55 - 126
   Google Scholar
• Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology 2003; 185:229 - 240
   PubMed Web of Science ®Google Scholar
• Rychly DJ, Dipiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005; 25:1181 - 1192
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 2006; 20:1181 - 1195
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098 - 1104
   PubMed Web of Science ®Google Scholar
• Theis VS, Rhodes JM. Minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 7:19 - 30
   Google Scholar
• Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48:319 - 324
   PubMed Web of Science ®Google Scholar
• Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007; 52:1481 - 1484
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83:181 - 194
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007; 109:2182 - 2189
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456 - 473
   PubMed Web of Science ®Google Scholar
• Fraser G, Smith CA, Imrie K, Meyer R, Hematology Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 2007; 14:96 - 109
   PubMedGoogle Scholar
• Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 2006; 65:48 - 53
   Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56:2886 - 2895
   PubMed Web of Science ®Google Scholar
• Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gómez-Reino JJ, BIOBADASER and EMECAR Groups. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66:880 - 885
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018 - 1028
   PubMed Web of Science ®Google Scholar
• Descotes J, Vial T. House RV, Descotes J. Flu-like syndromes and cytokines. Cytokines in Human Health: Immunotoxicology, Pathology and Therapeutic Applications 2007; Totowa NJ Humana Press 193 - 204
   Google Scholar
• Wing M. Monoclonal antibody first dose cytokine release syndromes—mechanisms and prediction. J Immunotoxicol 2008; 5:11 - 15
   PubMed Web of Science ®Google Scholar
• Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 1995; 105:23 - 29
   PubMed Web of Science ®Google Scholar
• Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13:725 - 732
   PubMed Web of Science ®Google Scholar
• Van Der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, Van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115:807 - 811
   PubMed Web of Science ®Google Scholar
• Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008; 37:381 - 387
   PubMed Web of Science ®Google Scholar
• Jakobovits A, Amado RG, Yang X, Roskos L, schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007; 25:1134 - 1143
   PubMed Web of Science ®Google Scholar
• Mukovozov I, Sabljic T, Hortelano G, Ofosu FA. Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thromb Haemost 2008; 99:874 - 882
   PubMed Web of Science ®Google Scholar
• De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007; 28:482 - 490
   PubMed Web of Science ®Google Scholar
• Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008; 333:1 - 9
   PubMed Web of Science ®Google Scholar
• Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, et al. Recommendations for the design, optimization and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007; 321:1 - 18
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109 - 1117
   PubMed Web of Science ®Google Scholar
• Chávez-López MA, Delgado-Villafaña J, Gallaga A, Huerta-Yáñez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol (Madr) 2005; 33:291 - 292
   PubMedGoogle Scholar
• Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab—report of a case. Eur J Gastroenterol Hepatol 2004; 16:627 - 630
   PubMed Web of Science ®Google Scholar
• Baudouin V, Crusiaux A, Haddad E, Schandene L, Goldman M, Loirat C, Abramowicz D. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003; 76:459 - 463
   PubMed Web of Science ®Google Scholar
• Pharand C, Palisaitis DA, Hamel D. Potential anaphylactic shock with abciximab readministration. Pharmacotherapy 2002; 22:380 - 383
   PubMed Web of Science ®Google Scholar
• Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV Jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 2002; 8:186 - 191
   PubMed Web of Science ®Google Scholar
• Dempster AM. Nonclinical safety evaluation of biotechnologically derived pharmaceuticals. Biotechnol Annu Rev 2000; 5:221 - 258
   PubMedGoogle Scholar
• Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov 2002; 1:469 - 475
   PubMed Web of Science ®Google Scholar
• Brennan FR, Shaw L, Wing MG, Robinson C. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges. Mol Biotechnol 2004; 27:59 - 74
   PubMed Web of Science ®Google Scholar
• Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 2007; 6:120 - 126
   PubMed Web of Science ®Google Scholar
• Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006; 29:1 - 9
   PubMed Web of Science ®Google Scholar
• ICH guideline S6: Preclinical safety evaluation of biotechnology-derived pharmaceuticals 1997; document available at http://www.ich.org/LOB/media/MEDIA503.pdf.
   Google Scholar
• ICH guideline S8: Immunotoxicity studies for human pharmaceuticals 2005; document available at http://www.ich.org/LOB/media/MEDIA1706.pdf.
   Google Scholar
• Descotes J. Methods of evaluating immunotoxicity. Expert Opin Drug Metab Toxicol 2006; 2:249 - 259
   PubMed Web of Science ®Google Scholar
• Dean JH, Padarathsingh ML, Jerrells TR. Assessment of immunobiological effects induced by chemicals, drugs and food additives I. Tier testing and screening approach. Drug Chem Toxicol 1979; 2:5 - 17
   PubMed Web of Science ®Google Scholar
• Herzyk DJ, Holsapple M. Immunotoxicity evaluation by immune function tests: focus on the T-dependent antibody response (TDAR). J Immunotoxicol 2007; 4:143 - 147
   PubMed Web of Science ®Google Scholar
• Ladics GS. Primary immune response to sheep red blood cells (SRBC) as the conventional t-cell dependent antibody response (TDAR) test. J Immunotoxicol 2007; 4:149 - 152
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Kim C. T-dependent antigen response (TDAR) tests: meta-analysis of results generated across multiple laboratories. J Immunotoxicol 2007; 4:159 - 164
   PubMed Web of Science ®Google Scholar
• Descotes J, Ravel G. Role of NK cells in immunotoxicity: an update. Exp Rev Clin Immunol 2005; 1:605 - 610
   Google Scholar
• Ponce R. Adverse consequences of immunostimulation. J Immunotoxicol 2008; 5:33 - 41
   PubMed Web of Science ®Google Scholar
• St Clair EW. The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest 2008; 118:1344 - 1347
   PubMed Web of Science ®Google Scholar
• EMEA. Guideline on the immunogenicity assessment of biotechnology-derived therapeutic proteins 2007; document available at: http://www.emea.europa.eu/pdfs/human/biosimilar/1432706en.pdf.
   Google Scholar
• Gourley I, Descotes J. Herzyk D, Bussiere J. Bridging immunotoxicology to clinical drug development. Immunotoxicology Strategies for Pharmaceutical Safety Assessment 2008; New York John Wiley & Sons 375 - 384
   Google Scholar
• O'Gorman MRG, Donnenberg AD. Handbook of Human Immunology 2008; 2nd edition Boca Raton CRC Press
   Google Scholar